midas2
Bayesian Platform Design with Subgroup Efficacy Exploration(MIDAS-2)
The rapid screening of effective and optimal therapies from large numbers of candidate combinations, as well as exploring subgroup efficacy, remains challenging, which necessitates innovative, integrated, and efficient trial designs(Yuan, Y., et al. (2016) doi:10.1002/sim.6971). MIDAS-2 package enables quick and continuous screening of promising combination strategies and exploration of their subgroup effects within a unified platform design framework. We used a regression model to characterize the efficacy pattern in subgroups. Information borrowing was applied through Bayesian hierarchical model to improve trial efficiency considering the limited sample size in subgroups(Cunanan, K. M., et al. (2019) doi:10.1177/1740774518812779). MIDAS-2 provides an adaptive drug screening and subgroup exploring framework to accelerate immunotherapy development in an efficient, accurate, and integrated fashion(Wathen, J. K., & Thall, P. F. (2017) doi:10.1177/1740774517692302).
- Version1.1.0
- R versionunknown
- LicenseGPL-3
- Needs compilation?No
- Last release07/14/2023
Team
Su Liwen
Insights
Last 30 days
Last 365 days
The following line graph shows the downloads per day. You can hover over the graph to see the exact number of downloads per day.
Data provided by CRAN
Binaries
Dependencies
- Imports3 packages